ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1324

Visceral Fat Deposition Associated with Pain in Osteoarthritis

Shanshan Li 1, Nancy Desai2, Tuhina Neogi 3, Ann Schwartz 4, Lavalley Michael 1, Na Wang 3, Xianbang Sun 1, Michael Nevitt 5, Beth Lewis 6, Ali Guermazi 2, Frank Roemer 7, Neil Segal 8 and David Felson 9, 1Boston University, Boston, 2Boston Medical Center, Boston, 3Boston University School of Medicine, Boston, MA, 4University of California San Francisco, San Francisco, 5University of California at San Francisco, San Francisco, CA, 6University of Alabama at Birmingham, Birmingham, AL, 7University of Erlangen-Nuremberg, Erlangen, Germany, 8University of Kansas Medical Center, Kansas City, KS, 9Boston University School of Medicine, Department of Rheumatology, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fat, Osteoarthritis, pain and adipocytokines

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Animal model studies have demonstrated the significant role of inflammation in the pathogenesis of osteoarthritis (OA) and of pain.  Visceral fat, rather than subcutaneous fat, is a major source of proinflammatory cytokines and adipokines.  In this study, we examined whether amount of visceral fat was associated with the risk of knee OA or musculoskeletal pain.  

Methods: Participants in the Multicenter Osteoarthritis Study (MOST), a NIH funded longitudinal cohort study of persons at risk of or with knee OA underwent whole body dual energy x-ray absorptiometry (DEXA) scans at baseline that were assessed for total body fat as well as visceral fat and subcutaneous fat in the torso.  In addition, participants had knee x-rays, rated severity of their knee pain and identified sites of joint pain on a body homunculus at the baseline, 30 month, and 60 month study visits.  The association between the size of the fat depots with structural outcomes from baseline through 60 months (incident x-ray OA, MRI cartilage loss and worsening synovitis scores) and with pain outcomes over the same period (worsening pain; widespread pain and the number of painful joint sites) was assessed.  We tested the association of sex specific quintiles of fat depot size with OA and pain outcomes performing regression analysis adjusted for age, sex, race, education, smoking, physical activity and BMI.  For pain outcomes, we also adjusted for depressive symptoms and for all outcomes, adjusted for baseline status of the outcome (e.g. for WOMAC pain change, we adjusted for WOMAC pain at baseline).

Results: We studied 2,961 participants, of whom, 60.7% were women, mean age was 62.5 years and BMI 30.5 kg/m2.  After adjustment for covariates including BMI, we found no association of any fat depot size with incident x-ray OA, cartilage loss or worsening synovitis on MRI (see figures below).  On the other hand, total body fat and visceral fat deposit size were associated with worsening knee pain. Visceral fat in addition was associated with the number of painful joints and similar results were seen in the analyses of incident widespread pain. Subcutaneous fat was not associated with any of these pain measures. In these analyses, fat depots were associated with OA outcomes before analytic adjustment for BMI but positive results for only pain outcomes persisted after BMI adjustment.

Conclusion:

Visceral fat and total body fat are associated with increased musculoskeletal pain. We found no relationship between body fat and structural changes in OA. Further investigation into identification of specific inflammatory markers produced by body visceral fat may provide further insight into these findings.


Visceral graph 1

Figure 1. Association Between Fat Depots and Structural Outcomes


Visceral graph 2

Figure 2. Association Between Fat Depots and Pain Outcomes


Disclosure: S. Li, None; N. Desai, None; T. Neogi, MerckSerono, 5, Novartis, 5; A. Schwartz, None; L. Michael, None; N. Wang, None; X. Sun, None; M. Nevitt, None; B. Lewis, None; A. Guermazi, AstraZeneca, 5, BICL, 1, Boston Imaging Core Lab (BICL), 1, Galapagos, 5, MerckSerono, 5, Pfizer, 5, Roche, 5, Shareholder BICL,LLC, 1, TissueGene, 5; F. Roemer, BICL, 1, Boston Imaging Core Lab, 1, 6, Shareholder BICL,LLC, 1; N. Segal, University of Kansas Medical Center, 3; D. Felson, None.

To cite this abstract in AMA style:

Li S, Desai N, Neogi T, Schwartz A, Michael L, Wang N, Sun X, Nevitt M, Lewis B, Guermazi A, Roemer F, Segal N, Felson D. Visceral Fat Deposition Associated with Pain in Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/visceral-fat-deposition-associated-with-pain-in-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/visceral-fat-deposition-associated-with-pain-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology